The partition of nutrients between mother and conceptuses in the pregnant rat

J. Frazer,A. Huggett

DOI: https://doi.org/10.1113/jphysiol.1970.sp009094

1970-05-01

Abstract:1. Diminishing the food supply to pregnant rats was associated with a subnormal degree of foetal loss among the larger litters, but a greatly lowered intake increased this foetal loss.

What problem does this paper attempt to address?

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Ping Wan,Jianjun Zhang,Xidai Long,Qigen Li,Ning Xu,Ming Zhang,Xiaosong Chen,Longzhi Han,Qiang Xia

DOI: https://doi.org/10.1097/MEG.0000000000000070

2014-01-01

European Journal of Gastroenterology & Hepatology

Abstract:Objective The aim of this study was to assess serum levels of presurgical alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9) as prognostic markers in patients with hepatic carcinoma after liver transplantation (LT). Methods A total of 226 patients were recruited for the analysis of serum AFP and CA19-9 levels, on the basis of which the tumor marker type (TMT) was defined and evaluated for prognostic prediction. Overall survival (OS) and relapse-free survival (RFS) were analyzed using Kaplan-Meier curves, and univariate and multivariate Cox models. Results One-year and 5-year OS were 79.0 and 58.0%, respectively, whereas RFS were 70.3 and 62.2%, respectively, in this cohort of patients. There were six variables predicting both OS and RFS, including TMT, tumor size, number of tumor lesions, extrahepatic or vascular invasion, and histopathological grade. Among these, TMT, tumor size, and extrahepatic invasion were all independent predictors of OS and RFS among these patients. Further, on the basis of TMT, novel LT selection criteria for patients with hepatic carcinoma, which supplemented the Milan criteria, were adopted, because the patients within the Milan criteria (n=107) and those exceeding Milan but fulfilling the proposed criteria (n=30) had similar 5-year OS (77.8 vs. 79.3%, P=0.862) and RFS (85.5 vs. 75.1%, P=0.210) rates. Conclusion The data from this study showed that serum levels of preoperative AFP and CA19-9 were able to predict survival of patients with hepatic carcinoma after LT. This study included novel criteria, adding serum AFP and CA19-9 levels to the selection criteria for LT eligibility of patients, in addition to the Milan criteria.
Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study

Junjun Jia,Chenyuan Ding,Mengjie Mao,Feng Gao,Zhou Shao,Min Zhang,Shusen Zheng

DOI: https://doi.org/10.1186/s12876-024-03298-5

2024-07-30

Abstract:Background: Hepatocellular carcinoma is a highly lethal tumor worldwide, and China has a correspondingly high incidence and mortality rate. For patients with unresectable hepatocellular carcinoma, the prognosis is often poor. The objective of this retrospective study was to investigate the effects of conversion therapies on these patients. Methods: The study included patients between the ages of 18 and 75 who were initially diagnosed with unresectable hepatocellular carcinoma and received conversion therapy. After completing surgery, the patients underwent pathological diagnosis, which showed complete necrosis. The study was conducted retrospectively at the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2019 to December 2021. The main objectives of the study were to evaluate the overall survival and recurrence-free survival. Results: A total of 60 patients who met the inclusion criteria were enrolled. The median age of the patients was 56.6 ± 9.5 years, and 85% of them were male. The one-year overall survival rate (OS) was 98.3%, and the three-year OS was 95.6%. The one-year recurrence-free survival rate (RFS) was 81.1%, and the three-year RFS was 71.4%. In subgroup analysis, there was no statistically significant difference in RFS between patients with BCLC stages 0-A and BCLC stages B-C (p = 0.296). Additionally, there was no statistically significant difference in RFS between patients who received postoperative new adjuvant therapy and those who did not (p = 0.324). Conclusions: Conversion therapy followed by surgical resection could be a promising treatment for patients with initially unresectable hepatocellular carcinoma, and the prognosis is good with a pathological complete response.
Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Li-Fu Kuo,Wen-Chun Liu,Ming-Feng Li,Fu-Huan Huang,Chu-Kuang Chou,Tsung-Hsien Chen,Yi-Tseng Tsai,Ping-I Hsu,Chao-Jen Li,I-Ting Wu,Kun-Feng Tsai

DOI: https://doi.org/10.1159/000542291

2024-10-28

Oncology

Abstract:Introduction: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5-15.3 months with a 39.1-42.5% tumor response rate. In comparison, ICIs have a 12-14 month OS rate with a 26-33% tumor response rate. Given these promising responses, this study evaluates the efficacy of conversion therapy with curative intent following HAIC or ICIs, focusing on survival outcomes. Methods: We retrospectively analyzed 80 patients with advanced or TACE-unsuitable intermediate HCC. Patients completed two HAIC or four ICI cycles, followed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria imaging. Based on demographics, cirrhosis status, Barcelona Clinic Liver Cancer classification (BCLC) stage, treatment responses, and treatment modality, survival impacts were analyzed. OS was compared between HAIC and immunotherapy groups. The effect of conversion therapy with curative intent on survival outcomes was analyzed using a Cox regression model. Results: Among the 80 patients, 26 achieved positive response (CR/PR) with HAIC or ICIs, and 9 of them subsequently underwent conversion therapy with curative intent. Key prognostic factors included Child-Pugh stage B versus A (HR = 2.21, p = 0.041), BCLC stage C versus B (HR = 4.38, p = 0.011), and elevated alpha-fetoprotein levels (HR = 5.02, p < 0.001). Positive responders saw substantial survival benefits (HR = 0.26, p = 0.001). Patients undergoing conversion therapy exhibited significantly enhanced survival. Median OS was 13.58 months with standard therapy, while the curative intent surgery group did not reach the median OS (p = 0.002). For CR/PR patients, 48-month survival was 75.0% for the curative surgery group versus 38.0% for standard treatment. Conclusion: Conversion therapy with curative intent following HAIC or ICIs might enhance survival in patients with advanced or TACE-unsuitable intermediate-stage HCC.
A glycopeptide extract can inhibit cytotoxic T lymphocyte-target cell conjugation in an H-2-restricted manner.

N. Pimlott,R. Miller

DOI: https://doi.org/10.4049/jimmunol.133.4.1763

1984-10-01

Abstract:Glycopeptides extracted from P815, a DBA/2 (H-2d) mastocytoma, were able to inhibit conjugate formation between anti-H-2d CTL and an H-2d target, but were not able to inhibit conjugate formation between anti-H-2k or anti-H-2b CTL and an appropriate target. This genetically specific effect was seen for CTL generated in primary bulk cultures and for long-term CTL lines, and was observed regardless of the strain combinations used to generate CTL. The phenomenon was quantitatively reproducible between independent experiments and between three separate preparations of P815 glycopeptide. These results suggest that recognition by CTL involves cell surface carbohydrate groups, and that the structure of these groups is influenced by H-2.
Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study

Ruyu Han,Leijuan Gan,Liyu Sun,Mengran Lang,Xindi Tian,Kangwei Zhu,Lu Chen,Guangtao Li,Tianqiang Song

DOI: https://doi.org/10.2147/jhc.s482803

2024-09-28

Journal of Hepatocellular Carcinoma

Abstract:Ruyu Han, 1, &ast Leijuan Gan, 1, &ast Liyu Sun, 1 Mengran Lang, 2 Xindi Tian, 1 Kangwei Zhu, 1 Lu Chen, 1 Guangtao Li, 1 Tianqiang Song 1 1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China; 2 Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tianqiang Song, Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China, Tel +86-22-23340123, Fax +86-22-23537796, Email Purpose: This study aimed to investigate the benefit of conversion therapy for patients with unresectable hepatocellular carcinoma (HCC). Patients and Methods: A retrospective cohort study was conducted involving 40 patients initially deemed unresectable HCC (uHCC). They received surgery following successful conversion therapy involving lenvatinib. The patients were matched in a 1:1 ratio to with a control group who underwent direct surgery, based on pre-treatment clinical data. Results: The median recurrence-free survival (RFS) duration for the conversion therapy cohort was notably longer than that of the direct surgery cohort (25 months vs 11 months). Furthermore, the 1- and 2-year RFS rates were significantly higher in the conversion therapy group compared to the direct surgery group (1 year: 70.5% vs 40.1%; 2 years: 49.0% vs 19.1%). The survival curves indicated a statistically significantly longer RFS in the conversion therapy cohort compared to the direct surgery cohort (P = 0.007). While patients achieving good remission based on both RECIST 1.1 and mRECIST criteria showed superior median RFS, no significant disparity was observed in the survival curves. The subgroup analysis revealed significantly improved prognosis among patients in the conversion therapy group who were male, older, had a history of alcohol consumption, were non-smokers, had liver cirrhosis, possessed Child-Pugh A liver function, had a tumor diameter exceeding 5 cm, and had an AFP ≥ 400 ng/mL. Among the cohort of 40 patients, only 8 individuals encountered severe adverse reactions, which were managed through dose reduction. None of the patients experienced multiple severe adverse reactions concurrently. Conclusion: For patients with unresectable hepatocellular carcinoma, conversion therapy offers a significantly better prognosis than direct surgery for uHCC patients. Keywords: hepatocellular carcinoma, conversion therapy, recurrence-free survival, hepatic resection Hepatocellular carcinoma (HCC) presents a formidable challenge to public health, characterized by high incidence and mortality rates compared to other malignancies. 1 The primary radical interventions for HCC encompass hepatic resection (HR), liver transplantation (LT), and radiofrequency ablation (RFA). 2 These modalities exclusively recommended for patients in the early stages. 3 Unfortunately, the majority of HCC cases are diagnosed at intermediate to advanced stages, precluding the feasibility of surgical interventions. 4,5 Historically, therapeutic options for these patients were constrained due to the absence of effective pharmaceutical interventions. 6 However, the advent of targeted therapies and immunotherapies has substantially broadened the therapeutic armamentarium for HCC, yielding increasingly efficacious treatments. 7–9 Consequently, the landscape of therapeutic options for patients with intermediate and advanced HCC has progressively expanded. In recent years, conversion therapy has emerged as a key component in the diagnostic and therapeutic strategy for intermediate and advanced HCC. 10,11 Conversion therapy aims to offer localized or systemic treatment to patients initially deemed unresectable, potentially enabling them to undergo radical treatment. 5 Such patients can be categorized into two distinct groups. One category comprises those who are unresectable due to -Abstract Truncated-

oncology
[The kidney in shock. Changes of some hemodynamic and bio-humoral parameters. II].

G. Colì,A. Donati,G. Grillone,L. Marinelli,L. Piccinni,R. Prandini,S. Stefoni,A. Zanoni

1981-10-15

Abstract:In our experiments on 5 pigs of weight between 40-50 kg we've noticed changes of the parameters occurring precociously during the initial stage of the shock. Particularly we observed a sudden reduction of diuresis reaching total anuria in 15 min and persistence of this anuria for the entire time of the shock (120 min). Immediately after introduction of the removed blood the arterial pressure and the diuresis return to normal value. Concerning the blood flow in renal artery it was observed a gradual decreasing to 10-30 ml/min (normal value = 120-180 ml/min). After the restoration of the blood volume we did'nt notice a clean resumption of the flow although arterial pressure reached normal levels (flow value = 70% of the basal value). The hematic level of K+ undergoes a sudden increase that reaches. Maximal level compatible with animal's life. Within 45-60 min from the beginning of the shock and than decrease with restarting of the diuresis. Creatinine reaches 2 mg/ml in 60 min and remain constant during the following 120 min. The value of the plasma renin were precociously raised, reaching values particularly elevated after 90-120 min from the beginning of the shock and decreasing rapidly with the introduction of the removed blood (parallel behaviour of the arterial pressure).
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

Xingzhi Li,Jie Chen,Xiaobo Wang,Tao Bai,Shaolong Lu,Tao Wei,Zhihong Tang,Chengwen Huang,Bin Zhang,Bowen Liu,Lequn Li,Feixiang Wu

DOI: https://doi.org/10.3389/fonc.2023.1110689

IF: 4.7

2023-01-30

Frontiers in Oncology

Abstract:Purpose To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death protein-1 (PD-1) inhibitors (LTP) for initially unresectable hepatocellular carcinoma (iuHCC). Methods Data on 94 consecutive patients with iuHCC who received LTP conversion therapy from November 2019 to September 2022 were retrospectively analyzed. Early tumor response was reported when patients showed complete or partial response at the time of their first follow-up (4–6 weeks) after initial treatment, in accordance with mRECIST. The endpoints consisted of conversion surgery rate, overall survival (OS), and progression-free survival (PFS). Results Early tumor response was found in 68 patients (72.3%) and not in the remaining 26 patients (27.7%) in the entire cohort. Early responders had a significantly higher conversion surgery rate than non-early responders (44.1% vs. 7.7%, p=0.001). Early tumor response was the only factor independently associated with successful conversion resection, as indicated by multivariate analysis (OR=10.296; 95% CI: 2.076–51.063; p=0.004). Survival analysis showed that early responders had longer PFS (15.4 vs. 7.8 months, p=0.005) and OS (23.1 vs. 12.5 months, p=0.004) than non-early responders. Early responders who underwent conversion surgery also had significantly longer median PFS and OS (not reached, not reached) than those who did not (11.2 months, p=0.004; 19.4 months, p<0.001). In multivariate analyses, early tumor response was identified as an independent prognostic factor for longer OS (HR=0.404, 95% CI: 0.171–0.954; p=0.039). Successful conversion surgery was also an independent predictive factor for longer PFS (HR=0.248, 95% CI: 0.099–0.622; p=0.003) and OS (HR=0.147, 95% CI: 0.039–0.554; p=0.005). Conclusions Early tumor response is an important predictive marker for successful conversion surgery and prolonged survival in patients with iuHCC treated using LTP conversion therapy. Conversion surgery is necessary to improve survival during conversion therapy, particularly for early responders.

oncology
1 Predictive and Prognostic Value of Hepatic Steatosis 2 in Conversion Therapy for Colorectal Liver-limited 3 Metastases 4

Mi Jian,Wenju Chang,Li Ren,Tianyu Liu,Yijiao Chen,Ye Wei,Qi Lin,Jianmin Xu,Xinyu Qin

DOI: https://doi.org/10.20944/preprints201811.0014.v1

2018-01-01

Abstract:This study is aimed to assess the role of hepatic steatosis (HS) on outcome of conversion 15 therapy for patients with initially unresectable synchronous colorectal liver-limited metastases 16 (CLLMs). We identified 346 patients with initially unresectable CLLMs received conversion therapy 17 under the guidance of multidisciplinary team (MDT) in Zhongshan hospital (2013 to 2016). HS 18 status of all patients was evaluated before the first circle of conversion therapy. The objective 19 response rate (ORR), hepatectomy rate, predictor of conversion hepatectomy, and overall survival 20 (OS) were compared using propensity-score matching (PSM). Predictive value of HS in conversion 21 hepatectomy was validated with a separate cohort of 60 patients initially unresectable CLLMs who 22 received conversion therapy (2017 to 2018). Before conversion therapy start, 108 (31.2%) patients 23 were detected with HS status. In study set after PSM, compared with non-HS group, HS group 24 supplied improved ORR (36.7% vs 23.9%, P=0.020), hepatectomy rate from MDT (27.7% vs. 16.9%, 25 P<0.001) following conversion therapy. Multivariate analysis confirmed that HS (OR, 5.234; 95%CI, 26 2.398-11.423, P<0.001), targeted therapy and transarterial chemoembolization treatment were 27 independent predictors of hepatectomy rate. In the validation cohort, patients with HS had an 28 improved conversion hepatectomy rate (43.7% vs. 15.9%, P=0.038) following conversion therapy. 29 Hepatic steatosis status could be a predictor of conversion hepatectomy in patients with 30 synchronous colorectal liver-limited metastases. This effect appears to be independent of use of 31 targeted therapy. 32
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients

Takeshi Hatanaka,Satoru Kakizaki,Atsushi Hiraoka,Toshifumi Tada,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hidenori Toyoda,Chikara Ogawa,Hiroki Nishikawa,Takashi Nishimura,Kazuhito Kawata,Hisashi Kosaka,Atsushi Naganuma,Yutaka Yata,Hideko Ohama,Hidekatsu Kuroda,Tomomitsu Matono,Tomoko Aoki,Yuki Kanayama,Kazunari Tanaka,Fujimasa Tada,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Taeang Arai,Michitaka Imai,Shinichiro Nakamura,Hirayuki Enomoto,Masaki Kaibori,Yoichi Hiasa,Masatoshi Kudo,Takashi Kumada,Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)

DOI: https://doi.org/10.1111/apt.18237

2024-09-04

Abstract:Aim: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) and complete response (CR) cases. Methods: In this retrospective multicentre study, we included a total of 946 uHCC patients treated with atezolizumab and bevacizumab (Atez/Bev) from September 2020 to September 2023. Results: Out of the patients, 43 (4.5%) received conversion therapy following Atez/Bev treatment. The overall response rate was 65.1% and 23.7% in the conversion and non-conversion group, respectively, with a statistical significance (p < 0.001). Multivariate analyses identified that BCLC stage B or an earlier stage (p = 0.045), absence of macrovascular invasion and extrahepatic spread (p = 0.045), and a low value of neutrophil to lymphocyte ratio (p = 0.04) were significantly favourable predictive factors associated with conversion therapy. The conversion group showed significantly better survival compared to the non-conversion group (p < 0.001). In the landmark analysis at 6, 12 and 18 months, the conversion group exhibited better survival compared to PR patients in the non-conversion group (p = 0.04, 0.01 and 0.03, respectively) and there were no significant differences in the overall survival (OS) between the conversion group and patients who achieved a CR (p = 0.7, 1.0 and 0.3, respectively). Conclusions: Patients with low tumour burden and low value of NLR were more likely to undergo conversion therapy. The OS of patients undergoing conversion therapy showed better survival compared to those achieving PR and was comparable to those with CR patients. Conversion therapy could be considered if feasible.
Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study

Zifeng Ma,Zhiyu Xiao,Pengfei yin,Kai Wen,Weidong Wang,Yongcong Yan,Zijian Lin,Zonglin Li,Haikuo Wang,Jianlong Zhang,Kai Mao

DOI: https://doi.org/10.1097/js9.0000000000001193

2024-02-14

International Journal of Surgery

Abstract:Objective: The objective of this study is to evaluate and compare the survival benefit and safety of surgery following conversion therapy versus surgery alone in patients diagnosed with surgically resectable hepatocellular carcinoma (HCC) at China Liver Cancer Staging (CNLC) IIb/IIIa stage. Methods: A total of 95 patients diagnosed with surgically resectable CNLC IIb/IIIa HCC were retrospectively enrolled in our study from November 2018 to December 2022. Among them, 30 patients underwent conversion therapy followed by hepatectomy, while the remaining 65 received surgery alone. The primary endpoint was recurrence-free survival (RFS). Propensity score matching (PSM) was employed to minimize bias in the retrospective analysis. Results: Compared to the surgery alone group, the conversion therapy group demonstrated a significantly prolonged median RFS (17.1 vs. 7.0 months; P =0.014), a reduced incidence of microvascular invasion (MVI, 23.3% vs. 81.5%; P <0.001), and a comparable rate of achieving Textbook Outcome in Liver Surgery (TOLS, 83.3% vs. 76.9%; P =0.476). Multivariate analysis indicated that conversion therapy was independently associated with improved RFS after hepatectomy (HR=0.511, P =0.027). The same conclusions were obtained after PSM. Conclusions: The findings of our study offer preliminary evidence that preoperative conversion therapy significantly prolongs RFS in patients with surgically resectable HCC at CNLC IIb/IIIa stage. Furthermore, combining conversion therapy and hepatectomy represents a relatively safe treatment strategy.

surgery
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

Zhen-Xin Zeng,Jia-Yi Wu,Jun-Yi Wu,Zhi-Bo Zhang,Kai Wang,Shao-Wu Zhuang,Bin Li,Jian-Yin Zhou,Zhong-Tai Lin,Shu-Qun Li,Yi-Nan Li,Yang-Kai Fu,Mao-Lin Yan

DOI: https://doi.org/10.1159/000536376

2024-01-27

Liver Cancer

Abstract:Introduction: Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC). We aimed to explore the prognostic value of pathological response (PR) in patients with initially uHCC who underwent conversion surgery following triple therapy and identify predictors of major pathological response (MPR). Methods: A total of 76 patients with initially uHCC who underwent conversion surgery following triple therapy were retrospectively analyzed. PR was calculated as the proportion of nonviable tumor cell surface area of the whole tumor bed surface area. MPR was identified when PR was ≥90%. Pathological complete response (pCR) was defined as the absence of viable tumor cells. Results: MPR and pCR were identified in 53 (69.7%) and 25 (32.9%) patients, respectively. The 1- and 2-year overall survival in patients with MPR were significantly higher than in those without MPR (100.0% and 91.3% vs. 67.7% and 19.4%; p < 0.001). The corresponding recurrence-free survival was also improved in patients with MPR compared to those without (75.9% and 50.8% vs. 22.3% and 11.2%; p < 0.001). Similar results were observed among patients with pCR and those without. Patients who achieved MPR without pCR exhibited survival rates comparable to those of patients who achieved pCR. Baseline neutrophil-to-lymphocyte ratio ≥2.6 ( p = 0.016) and preoperative alpha-fetoprotein level ≥400 ng/mL ( p = 0.015) were independent predictors of MPR. Conclusion: The presence of MPR or pCR could improve prognosis in patients with initially uHCC who underwent conversion surgery following triple therapy. The PR may become a surrogate marker for predicting the prognosis of these patients.

oncology,gastroenterology & hepatology
Predictive and Prognostic Value of Hepatic Steatosis in Conversion Therapy for Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis

Mi Jian,Wenju Chang,Li Ren,Tianyu Liu,Yijiao Chen,Ye Wei,Qi Lin,Jianmin Xu,Xinyu Qin

DOI: https://doi.org/10.2147/cmar.s210185

2019-01-01

Cancer Management and Research

Abstract:Purpose: To evaluate the role of hepatic steatosis (HS) in patients with synchronous colorectal liver-limited metastases (CLLMs) undergoing conversion therapy. Patients and methods: From March 2013 to March 2017, a total of 406 patients with initially unresectable CLLMs accepted conversion therapy in multidisciplinary team (MDT). Before the implementation of conversion therapy, all patients underwent CT scan to assess the presence of hepatic steatosis and divided into the HS group (n = 124) and the non-HS group (n = 282). After using propensity score matching (PSM) to eliminate the potential confounding bias of the two groups, the conversion hepatectomy rate and long-term oncological survival in two groups were compared. Results: After 1:1 PSM, no significant difference was observed at baseline between patients in the HS group (n = 119) and the non-HS group (n = 119). Patients in the HS group had higher conversion hepatectomy rate from MDT evaluation (31.1% vs 18.5%, P = 0.029) and actual hepatectomy rate (30.2% vs 18.5%, P = 0.030), when compared with patients in the non-HS group, respectively. In addition, the HS group achieved better progression-free survival (PFS, P = 0.047) and overall survival (OS, P = 0.035) than that of the non-HS group. Multivariate logistic analysis confirmed that pretreatment HS was an independent predictor for conversion hepatectomy rate (OR, 2.393; 95% CI, 1.463-4.315, P = 0.001), and multivariate Cox analysis revealed that HS was an independent prognostic factor for PFS (HR, 0.493, 95% CI 0.281-0.866, P = 0.014) and OS (HR, 0.559, 95% CI 0.398-0.785, P = 0.001). Conclusion: For CLLM patients who underwent conversion therapy, hepatic steatosis could be an effective predictor for conversion hepatectomy rate and an independent prognostic factor for PFS and OS.
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Jiaqi Chen,Ding Zhang,Ying Yuan

DOI: https://doi.org/10.1007/s10238-022-00873-6

IF: 4.6

2022-01-01

Clinical and Experimental Medicine

Abstract:Curative surgery and locoregional therapy are radical therapies for patients with HCC. But more than 80% of HCC patients cannot be fitful for radical therapies because of local progression or distant metastasis at initial diagnosis. Among patients with unresectable locally advanced hepatocellular carcinoma (HCC), some patients can be converted to be technically resectable by conversion treatment and salvage surgery. For unresectable locally advanced hepatocellular, conversion treatment prior to salvage surgery with transcatheter arterial chemoembolization (TACE) and other locoregional therapies improve outcomes. PD-1/PD-L1 inhibitors as immune checkpoint inhibitor (ICI) therapy which show high antineoplastic activity in HCC patients by preclinical and clinical researches can also be a good choice for conversion therapy. PD-1/PD-L1 inhibitor combined with locoregional therapy plus antiangiogenic agents or not is most potential conversion therapy comparing to PD-1 inhibitor monotherapy and PD-1/PD-L1 inhibitor combined with antiangiogenic agents or CTLA-4 inhibitor. As more clinical evidence reported, PD-1/PD-L1 immunotherapy would be widely used in conversion treatment of locally advanced hepatocellular carcinoma.
[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Shu-sen Zheng,Xiao Xu,Ting-bo Liang,Wei-lin Wang,Yan Shen,Min Zhang,Jian Wu,An-wei Lu,Zhe-xin Shao

DOI: https://doi.org/10.3760/j:issn:0529-5815.2005.07.013

2005-01-01

Abstract:OBJECTIVE:To summarize the experience of liver transplantation (LT) for hepatocellular carcinoma (HCC) in one center and identify prognostic factors for survival.METHODS:The clinical data and survival results of 89 patients with HCC receiving LT from January 1999 to December 2003 were retrospectively analyzed and various clinicopathologic risk factors for actuarial survival and tumor free survival were evaluated by univariate and multivariate analysis.RESULTS:Six-month, 1-, and 2-year survival rates were 81.8%, 55.3% and 43.7%, respectively. The 6-month, 1-, and 2-year tumor free survival rates were 62.4%, 35.6% and 24.9%, respectively. The overall tumor recurrence and metastasis rate was 52.8%. In the univariate analysis, portal vein tumor thrombi (PVTT) (chi(2) = 15.14, P = 0.0001), tumor size (chi(2) = 15.05, P = 0.0001), hepatic cirrhosis background (chi(2) = 6.14, P = 0.0132), preoperative alpha-fetoprotein (AFP) level (chi(2) = 5.82, P = 0.0159) and histopathologic grading (chi(2) = 4.61, P = 0.0319) were found to be significantly associated with actuarial survival rate. Seven factors influencing tumor free survival included PVTT (chi(2) = 26.30, P < 0.0001), tumor size (chi(2) = 25.25, P < 0.0001), preoperative AFP level (chi(2) = 14.83, P = 0.0001), histopathologic grading (chi(2) = 12.54, P = 0.0004), tumor distribution (chi(2) = 12.73, P = 0.0004), number of nodules (chi(2) = 9.81, P = 0.0017) and cirrhosis background (chi(2) = 9.76, P = 0.0018). In the multivariate Cox regression analysis, the prognostic factors independently associated with patient survival were identified to be PVTT (RR = 4.721, P = 0.001), age (RR = 3.282, P = 0.007) and histopathologic grading (RR = 2.368, P = 0.037). For tumor free survival, histopathologic grading (RR = 3.739, P < 0.0001), PVTT (RR = 4.382, P = 0.001), cirrhosis background (RR = 0.421, P = 0.011), age (RR = 2.312, P = 0.027) and AFP (RR = 2.301, P = 0.047) were identified as prognostic parameters.CONCLUSIONS:LT is a good therapeutic option for strictly selected patients with HCC. PVTT and histopathologic grading are the most important factors of predicting outcomes of HCC patients undergoing LT. Further studies should be strengthened to establish a reliable and feasible selection criteria and an optimal prognosis scoring system for LT.
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

Xiao-Dong Zhu,Cheng Huang,Ying-Hao Shen,Bin Xu,Ning-Ling Ge,Yuan Ji,Xu-Dong Qu,Lingli Chen,Yi Chen,Mei-Ling Li,Jin-Jin Zhu,Zhao-You Tang,Jian Zhou,Jia Fan,Hui-Chuan Sun

DOI: https://doi.org/10.1245/s10434-022-12530-z

IF: 4.339

2022-09-30

Annals of Surgical Oncology

Abstract:Abstract Background Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. Methods A cohort of consecutive patients who received combined TKI/anti-PD-1 antibodies as first-line treatment for initially unresectable HCC at the authors’ hospital between August 2018 and September 2020 was eligible for this study. Patients who were responding to systemic therapy and met the criteria for hepatectomy underwent liver resection with curative intention. The study also investigated the association of clinical factors with successful conversion resection and postoperative recurrence. Results The study enrolled 101 patients including 24 patients (23.8 %) who underwent R0 resection a median of 3.9 months (interquartile range: 2.5–5.9 months) after initiation of systemic therapy. Patients with an Eastern cooperative oncology group performance status of 0, fewer intrahepatic tumors, or a radiographic response to systemic therapy were more likely to be able to receive curative resection. After a median follow-up period of 21.5 months, hepatectomy was independently associated with a favorable overall survival (hazard ratio [HR], 0.050; 95 % confidence interval [CI], 0.007–0.365; P = 0.003). For the 24 patients who underwent surgery, the 12-month recurrence-free survival and overall survival rates were respectively 75% and 95.8%. Achieving a pathologic complete response ( n = 10) to systemic therapy was associated with a favorable recurrence-free survival after resection, with a trend toward significance (HR, 0.345; 95% CI, 0.067–1.785; P = 0.187). Conclusions Selected patients with initially unresectable HCC can undergo hepatectomy after systemic therapy with combined TKI/anti-PD-1 antibodies. In this study, conversion resection was associated with a favorable prognosis.

oncology,surgery
ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Xiao-Dong Zhu,Cheng Huang,Ying-Hao Shen,Bin Xu,Ning-Ling Ge,Yuan Ji,Xu-Dong Qu,Lingli Chen,Yi Chen,Mei-Ling Li,Jin-Jin Zhu,Zhao-You Tang,Jian Zhou,Jia Fan,Hui-Chuan Sun

DOI: https://doi.org/10.1245/s10434-022-12653-3

IF: 4.339

2022-01-01

Annals of Surgical Oncology

Abstract:Background Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. Methods A cohort of consecutive patients who received combined TKI/anti-PD-1 antibodies as first-line treatment for initially unresectable HCC at the authors' hospital between August 2018 and September 2020 was eligible for this study. Patients who were responding to systemic therapy and met the criteria for hepatectomy underwent liver resection with curative intention. The study also investigated the association of clinical factors with successful conversion resection and postoperative recurrence. Results The study enrolled 101 patients including 24 patients (23.8 %) who underwent R0 resection a median of 3.9 months (interquartile range: 2.5-5.9 months) after initiation of systemic therapy. Patients with an Eastern cooperative oncology group performance status of 0, fewer intrahepatic tumors, or a radiographic response to systemic therapy were more likely to be able to receive curative resection. After a median follow-up period of 21.5 months, hepatectomy was independently associated with a favorable overall survival (hazard ratio [HR], 0.050; 95 % confidence interval [CI], 0.007-0.365; P = 0.003). For the 24 patients who underwent surgery, the 12-month recurrence-free survival and overall survival rates were respectively 75% and 95.8%. Achieving a pathologic complete response (n = 10) to systemic therapy was associated with a favorable recurrence-free survival after resection, with a trend toward significance (HR, 0.345; 95% CI, 0.067-1.785; P = 0.187). Conclusions Selected patients with initially unresectable HCC can undergo hepatectomy after systemic therapy with combined TKI/anti-PD-1 antibodies. In this study, conversion resection was associated with a favorable prognosis.
Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Weiwei Li,Yinxuan Pei,Zixiang Wang,Jinlong Liu

DOI: https://doi.org/10.3389/fonc.2022.930868

2022-08-01

Abstract:Background: Hepatocellular carcinoma (HCC) is a highly malignant disease with poor prognosis, and most cases were already considered unresectable at the time of presentation. Conversion therapy, as an emerging treatment, is designed to provide patients with initially unresectable hepatocellular carcinoma (uHCC) the opportunity to undergo radical resection. At present, conversion therapy for patients with uHCC remains controversial. Transarterial chemoembolization (TACE) is currently the most widely selected treatment for uHCC, but its efficacy as a conversion therapy remains controversial. Methods: We compared and evaluated the conversion rate for and tumor response to TACE monotherapy or combination therapy. Meanwhile, postoperative complications and overall survival (OS) in uHCC patients who underwent conversion therapy were also analyzed. Results: A total of 18 studies were included in this meta-analysis. The conversion rate for triple therapy [TACE in combination with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs)] was 42% [95% confidence interval (CI), 0.29-0.56], higher than any other group [TACE monotherapy: 10% (95% CI, 0.08-0.12), bigeminy therapy: 19% (95% CI, 0.06-0.36)]. Meanwhile, triple therapy yielded a better tumor response than TACE monotherapy or bigeminy therapy. Among the patients with successful surgical resection after conversion therapy, the pooled postoperative OS rates at 1, 2, and 5 years were 90% (95% CI, 0.81-0.97), 58% (95% CI, 0.42-0.73), and 42% (95% CI, 0.26-0.60), respectively, and the major postoperative complications were biliary leakage (7%; 95% CI, 0.03-0.12) and liver failure (3%; 95% CI, 0.00-0.07). Conclusion: TACE conversion therapies showed good conversion rates, especially the triple therapy of TACE in combination with TKIs and ICIs. Surgical resection after successful conversion therapy could maximize the outcome of patients with uHCC.
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab

Tatsuya Kikuchi,Yasuto Takeuchi,Kazuhiro Nouso,Kazuya Kariyama,Kenji Kuwaki,Junichi Toshimori,Shota Iwado,Akio Moriya,Hiroaki Hagihara,Hiroyuki Takabatake,Toshifumi Tada,Tetsuya Yasunaka,Masahiro Sakata,Masahiko Sue,Nozomi Miyake,Takuya Adachi,Nozomu Wada,Hideki Onishi,Hidenori Shiraha,Akinobu Takaki,Motoyuki Otsuka

DOI: https://doi.org/10.1111/liv.15907

IF: 8.754

2024-03-16

Liver International

Abstract:Background To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC). Methods In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first‐line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer‐free status were identified. Results Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p = .03) and tended to have lower Child‐Pugh scores and alpha‐fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1–13]; p = .04). Furthermore, 10 (66.7%) patients achieved cancer‐free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p

gastroenterology & hepatology
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study

Xiaoshi Zhang,Xiaodong Zhu,Jianhong Zhong,Yang Zhao,Xiaoyun Zhang,Wenwen Zhang,Feng Ye,Chaoxu Yang,Jun Xue,Rui Xiong,Jiabei Wang,Shunli Shen,Yangxun Pan,Dongxiao Li,Tianqiang Song,Xinyu Bi,Huichuan Sun,Bangde Xiang,Shanzhi Gu,Tianfu Wen,Shichun Lu,Yongjun Chen,Tao Yin,Lianxin Liu,Ming Kuang,Li Xu,Deyu Li,Jianqiang Cai

DOI: https://doi.org/10.1038/s41598-024-60379-x

IF: 4.6

2024-04-29

Scientific Reports

Abstract:Systemic therapy is typically the primary treatment choice for hepatocellular carcinoma (HCC) patients with extrahepatic metastases. Some patients may achieve partial response (PR) or complete response (CR) with systemic treatment, leading to the possibility of their primary tumor becoming resectable. This study aimed to investigate whether these patients could achieve longer survival through surgical resection of their primary tumor. We retrospectively collected data from 150 HCC patients with extrahepatic metastases treated at 15 different centers from January 1st, 2015, to November 30th, 2022. We evaluated their overall survival (OS) and progress-free survival (PFS) and analyzed risk factors impacting both OS and PFS were analyzed. Patients who received surgical treatment had longer OS compared to those who did not (median OS 16.5 months vs. 11.3 months). However, there was no significant difference in progression-free survival between the two groups. Portal vein invasion (P = 0.025) was identified as a risk factor for poor prognosis in patients, while effective first-line treatment (P = 0.039) and surgical treatment (P = 0.005) were protective factors. No factors showed statistical significance in the analysis of PFS. Effective first-line treatment (P = 0.027) and surgical treatment (P = 0.006) were both independent protective factors for prolonging patient prognosis, while portal vein invasion was an independent risk factor (P = 0.044). HCC patients with extrahepatic metastases who achieve PR/CR with conversion therapy may experience longer OS through surgical treatment. This study is the first to analyze the clinical outcomes of patients receiving surgical treatment for HCC with extrahepatic metastases.

multidisciplinary sciences
Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis

Yinbiao Cao,Haowen Tang,Bingyang Hu,Wenwen Zhang,Tao Wan,Jun Han,Tianyu Jiao,Junfeng Li,Xuerui Li,Zhanyu Yang,Zhe Liu,Minggen Hu,Weidong Duan,Chenggang Li,Zhiming Zhao,Shichun Lu

DOI: https://doi.org/10.1016/j.hpb.2023.03.004

IF: 3.842

2023-03-01

HPB

Abstract:BACKGROUND: Salvage surgery after conversion therapy with a combination of tyrosine kinase inhibitor and anti-programmed death-1 antibody has shown improved survival benefits in patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We aimed to compare the survival benefits in a retrospective cohort of patients with HCC with PVTT who underwent salvage surgery after conversion therapy and surgery alone.METHODS: From January 2015 to October 2021, we selected patients diagnosed with HCC with PVTT who underwent liver resection at Chinese PLA General Hospital. The primary endpoint in the comparison of survival benefits between conversion therapy and surgery-alone groups was recurrence-free survival. Propensity score matching was applied to reduce any potential bias in the study.RESULTS: The 6-, 12-, and 24-month recurrence-free survival rates in the conversion and surgery alone groups were 80.3% vs 36.5%, 65.4% vs 29.4%, and 56% vs 21%, respectively. On multivariable Cox regression analyses, conversion therapy significantly reduced HCC-related mortality and HCC recurrence rates compared with surgery alone.CONCLUSIONS: For patients with HCC with PVTT, surgery after conversion therapy is in relationship with increased survival in comparison with surgery alone.

gastroenterology & hepatology,surgery

The partition of nutrients between mother and conceptuses in the pregnant rat

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

A glycopeptide extract can inhibit cytotoxic T lymphocyte-target cell conjugation in an H-2-restricted manner.

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study

[The kidney in shock. Changes of some hemodynamic and bio-humoral parameters. II].

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

1 Predictive and Prognostic Value of Hepatic Steatosis 2 in Conversion Therapy for Colorectal Liver-limited 3 Metastases 4

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients

Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study

Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

Predictive and Prognostic Value of Hepatic Steatosis in Conversion Therapy for Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab

Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study

Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis